Answers are grounded in this paper and cite their sources.
Aberrant DNA methylation is a hallmark of colorectal cancer (CRC) and represents a potential therapeutic target. DNA methyltransferase inhibitors can induce sustained transcriptional and phenotypic reprogramming of tumor cells; however, the therapeutic vulnerabilities created by this reprogramming are not completely understood. Here, we investigated the effects of 5-azacitidine (5-AZA) in the human CRC cell lines HT-29 and DLD-1 and assessed whether epigenetic priming could subsequently be exploited using senolytic or immunotherapeutic approaches. Treatment with 5-AZA reduced cell proliferation and induced a senescent phenotype accompanied by increased expression of the cyclin-dependent kinase inhibitors CDKN1A and CDKN2B and anti-apoptotic BCL-2 family proteins as well as p16 expression on protein level. These changes were most pronounced in HT-29 cells. Pretreatment with 5-AZA sensitized HT-29 cells to navitoclax, a broad-spectrum BH3 mimetic, whereas the selective BCL-2 inhibitor venetoclax was less effective. In DLD-1 cells, both the senescent phenotype and sensitization to navitoclax were less pronounced, indicating that the response to epigenetic priming is dependent on tumor-cell context. By contrast, in an in vitro immunotherapy model using DLD-1 tumor cells, lymphocytes and a bispecific CD19 × CD3 T-cell engager (BiTE), pretreatment of tumor cells with 5-AZA enhanced T-cell-mediated cytotoxicity and increased IFN-γ production. Thus, 5-AZA induces therapeutically relevant reprogramming of CRC cells, sensitizing them to navitoclax while simultaneously increasing their susceptibility to T-cell-mediated elimination. These findings provide a rationale for further investigation of sequential treatment strategies combining epigenetic priming with senolytic or immunotherapeutic approaches.
No takes yet. Share an insight, caveat, or question.
Lisitsa et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: